Business
Hippofi Welcomes Scott Bauccio as New Head of Sales for Pur Biologics
Hippofi Welcomes Scott Bauccio as New Head of Sales for Pur Biologics.
About this update from Orhub, Inc.
[{"type":"text","content":"IRVINE, CA / ACCESSWIRE / January 23, 2024 / HippoFi's (OTC PINK:ORHB) biotechnology business PUR Biologics, proudly announces Scott Bauccio as its new Head of Sales. Utilizing his 20 years of sales management and his extensive network of industry- leading sales professionals, Bauccio is expanding the company's sales and distribution channels; already securing two new products: PURamnio (selling now) and PURpeptide (launching within 30 days)."We are excited to welcome Scott to our team. His proven success in driving growth and remarkable ability to establish a strong market presence is perfectly aligned with our objectives," says Ryan Fernan, Head of PUR Biologics.CJ Wiggins, Executive Chairman & CEO of HippoFi shared, "Scott's appointment is a tactical move to strengthen our leadership team at a pivotal time in our sales growth. His industry expertise and market insights are invaluable in our continuous pursuit of innovation and excellence in the biologic sector."In his previous role at Biogennix, as the Vice President of Sales & Business Development, Bauccio successfully established the company's ortho-spine biologic sales and distribution channels throughout the United States. Prior to Biogennix, his time at LDR Spinal Implants and Orthofix Spinal Implants, was marked by significant achievements and leadership awards for sales growth.Bauccio's appointment reflects the first of several strategic actions HippoFi will take in 2024 to further their commitment to leading the industry as the Authority in Regenerative Biologics.----About PUR BiologicsPUR Biologics, a wholly owned subsidiary of HippoFi, Inc. (OTCPK:ORHB), is a leading biologic company committed to supporting surgeons and hospitals in providing the best care for their patients. PUR Biologics' full line of biologic products currently include: advanced allografts and demineralized extracellular matrixes (d-ECM), innovative synthetic solutions, cellular derived tissues, and a future of next generation regenerative stem cell and growth factor driven therapeutics for treating osteoarthritis and cartilage regeneration.About HippoFi, Inc.HippoFi is a healthcare innovator and publicly traded company, delivering proprietary technologies in the multi-billion-dollar Spine, Orthopedic, and Cancer markets. The company's purpose is to improve patient car...